Excluded publicationsCode
Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Archives of Disease in Childhood. Nov 2003;88(11):969–973.6
Ashcroft D, Chen L-C, Garside R, Stein K, Williams H. Topical pimecrolimus for eczema. Cochrane Database of Systematic Reviews. 2007;4:4.3
Barba JF, Beirana A, Cohen V, et al. Pimecrolimus cream 1% is effective, well-tolerated and safe in infants and children with atopic eczema of the face. Journal of the European Academy of Dermatology & Venereology. 2003;17.5
Barbier N, Paul C, Luger T, et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. British Journal of Dermatology. Jan 2004;150(1):96–102.6
Beck LA. The efficacy and safety of tacrolimus ointment: a clinical review. Journal of the American Academy of Dermatology. Aug 2005;53(2 Suppl 2):S165–170.6
Berger TG, Duvic M, Van Voorhees AS, VanBeek MJ, Frieden IJ, American Academy of Dermatology Association Task F. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force.[erratum appears in J Am Acad Dermatol. 2006 Aug;55(2):271 Note: VanBeek, Marta J [added]]. Journal of the American Academy of Dermatology. May 2006;54(5):818–823.6
Bernard LA, Eichenfield LF. Topical immunomodulators for atopic dermatitis. Current Opinion in Pediatrics. Aug 2002;14(4):414–418.6
Beyerler M, Schmid-Grendelmeier P, Hafner J. Significantly elevated systemic levels after occlusive application of topical tacrolimus in atopic dermatitis. Dermatology. 2006;212(3):260–261.6
Bos JD. Topical tacrolimus and pimecrolimus are not associated with skin atrophy. British Journal of Dermatology. Feb 2002;146(2):342; author reply 343.5
Bos JD. Non-steroidal topical immunomodulators provide skin-selective, self-limiting treatment in atopic dermatitis. European Journal of Dermatology. Sep–Oct 2003;13(5):455–461.6
Breuer K, Braeutigam M, Kapp A, Werfel T. Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis. Dermatology. 2004;209(4):314–320.5
Breuer K, Werfel T, Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. American Journal of Clinical Dermatology. 2005;6(2):65–77.6
Burkhart CG, Burkhart CN. Tacrolimus and topical steroids: which is more effective? British Journal of Dermatology. Dec 2004;151(6):1281; author reply 1281–1282.5
Burkhart CN, Burkhart CG. Pilot study of patient satisfaction with nonfluorinated topical steroids compared with a topical immunomodulator in atopiform dermatitis. International Journal of Dermatology. Mar 2004;43(3):215–219.7
Callen J, Chamlin S, Eichenfield LF, et al. A systematic review of the safety of topical therapies for atopic dermatitis. British Journal of Dermatology. Feb 2007;156(2):203–221.6
Castro APBM. Calcineurin inhibitors in the treatment of allergic dermatitis. Jornal de Pediatria. Nov 2006;82(5 Suppl):S166–172.6
Cheer SM, Plosker GL. Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis. American Journal of Clinical Dermatology. 2001;2(6):389–406.6
Cho M, Puma I, Nguyen D, Schut R, Glesne L. Development of Kaposi’s sarcoma in an AIDS patient after treatment with topical tacrolimus. Journal of the American Academy of Dermatology. Jan 2004;50(1):149–150.6
Cohen B. Review of pimecrolimus cream 1% in children for the treatment of mild to moderate atopic dermatitis. Clinical Pediatrics. Jan 2007;46(1):7–15.6
Dahl RE, Bernhisel-Broadbent J, Scanlon-Holdford S, Sampson HA, Lupo M. Sleep disturbances in children with atopic dermatitis. Arch Pediatr Adolesc Med. August 1, 1995 1995;149(8):856–860.4
Eichenfield LF, Ho V, Matsunaga J, Leclerc P, Paul C, Hanifin JM. Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis. Journal of Dermatology. Apr 2007;34(4):231–236.6
Fivenson D, Arnold RJ, Kaniecki DJ, Cohen JL, Frech F, Finlay AY. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. J Manag Care Pharm. Sep–Oct 2002;8(5):333–342.6
Freeman AK, Serle J, VanVeldhuisen P, et al. Tacrolimus ointment in the treatment of eyelid dermatitis. Cutis. Apr 2004;73(4):267–271.6
Furue M, Terao H, Moroi Y, et al. Dosage and adverse effects of topical tacrolimus and steroids in daily management of atopic dermatitis. Journal of Dermatology. Apr 2004;31(4):277–283.6
Gianni LM, Sulli MM. Topical tacrolimus in the treatment of atopic dermatitis. Annals of Pharmacotherapy. Jul–Aug 2001;35(7–8):943–946.6
Hanifin JM, Paller AS, Eichenfield L, et al. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol. Aug 2005;53(2 Suppl 2):S186–194.6
Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. British Journal of Dermatology. Apr 2001;144(4):781–787.6
Hebert AA. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis. Clinical Therapeutics. Dec 2006;28(12):1972–1982.6
Hidalgo BP, Knight T, Burls A. A systematic review of effectiveness and cost effectiveness of tacrolimus ointment for topical treatment of atopic dermatitis in adults and children. Database of Abstracts of Reviews of Effects. 2007(4).3
Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4(37):1–91.3
Hon K-LE, Lam M-CA, Leung T-F, Chow C-M, Wong E, Leung AKC. Assessing itch in children with atopic dermatitis treated with tacrolimus: objective versus subjective assessment. Advances in Therapy. Jan–Feb 2007;24(1):23–28.7
Kang S. Tacrolimus ointment for adults with moderate to severe atopic dermatitis: a dose escalation study (abstract 1253). J Invest Dermatol. 1998;110:681.5
Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. Journal of the American Academy of Dermatology. Jan 2001;44(1 Suppl):S58–64.6
Katoh N, Hirano S, Yasuno H, Kishimoto S. Effects of tacrolimus ointment on facial eruption, itch, and scratching in patients with atopic dermatitis. Journal of Dermatology. Mar 2004;31(3):194–199.6
Kawakami T, Soma Y, Morita E, et al. Safe and effective treatment of refractory facial lesions in atopic dermatitis using topical tacrolimus following corticosteroid discontinuation. Dermatology. 2001;203(1):32–37.5
Kiebert G, Sorensen SV, Revicki D, et al. Atopic dermatitis is associated with a decrement in health-related quality of life. International Journal of Dermatology. 2002;41(3):151–158.6
Koo JY, Fleischer AB, Jr., Abramovits W, et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. J Am Acad Dermatol. Aug 2005;53(2 Suppl 2):S195–205.6
Korfitis C, Gregoriou S, Rallis E, Rigopoulos D. Pimecrolimus versus topical corticosteroids in dermatology. Expert Opinion on Pharmacotherapy. Jul 2007;8(10):1565–1573.6
Kreuter A, Hochdorfer B, Altmeyer P, Gambichler T. Pimecrolimus 1% cream for perianal atopic dermatitis. British Journal of Dermatology. Jan 2005;152(1):186–187.6
Kyllonen H, Remitz A, Mandelin JM, Elg P, Reitamo S. Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. British Journal of Dermatology. Jun 2004;150(6):1174–1181.2
Lan C-CE, Huang C-C, Chen Y-T, Wang L-F, Lin C-T, Chen G-S. Tacrolimus ointment for the treatment of atopic dermatitis: report of first clinical experience in Taiwan. Kaohsiung Journal of Medical Sciences. Jun 2003;19(6):296–304.6
Langeland T, Engh V. Topical use of tacrolimus and squamous cell carcinoma on the penis. British Journal of Dermatology. Jan 2005;152(1):183–185.6
Lawson V, Lewis-Jones MS, Finlay AY, Reid P, Owens RG. The family impact of childhood atopic dermatitis: the Dermatitis Family Impact Questionnaire. Br J Dermatol. Jan 1998;138(1):107–113.4
Linnet J, Jemec GB. An assessment of anxiety and dermatology life quality in patients with atopic dermatitis. Br J Dermatol. Feb 1999;140(2):268–272.3
Lonsdale-Eccles AA, Velangi S. Herpes simplex of the vulva evoked by topical tacrolimus treatment. Clinical & Experimental Dermatology. Jan 2005;30(1):95–96.6
Lubbe J, Friedlander SF, Cribier B, et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. American Journal of Clinical Dermatology. 2006;7(2):121–131.6
Milingou M, Antille C, Sorg O, Saurat J-H, Lubbe J. Alcohol intolerance and facial flushing in patients treated with topical tacrolimus. Archives of Dermatology. Dec 2004;140(12):1542–1544.6
Munzenberger PJ, Montejo JM. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Pharmacotherapy. Jul 2007;27(7):1020–1028.6
Nakagawa H. Comparative study of FK506 (tacrolimus) ointment vs alclometasone dipropionate ointment in atopic dermatitis (face and neck lesions) (abstract 1266). J Invest Dermatol. 1998;110:683.5
Nakagawa H. Comparison of the efficacy and safety of 0.1% tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis: review of randomised, double-blind clinical studies conducted in Japan. Clinical Drug Investigation. 2006;26(5):235–246.6
Nakahara T, Koga T, Fukagawa S, Uchi H, Furue M. Intermittent topical corticosteroid/tacrolimus sequential therapy improves lichenification and chronic papules more efficiently than intermittent topical corticosteroid/emollient sequential therapy in patients with atopic dermatitis. Journal of Dermatology. Jul 2004;31(7):524–528.6
Naylor M, Elmets C, Jaracz E, Rico JM. Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. Journal of Dermatological Treatment. Aug 2005;16(3):149–153.6
Pacor ML, Di Lorenzo G, Martinelli N, Mansueto P, Rini GB, Corrocher R. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clinical & Experimental Allergy. Apr 2004;34(4):639–645.3
Papp KA, Werfel T, Folster-Holst R, et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. Journal of the American Academy of Dermatology. Feb 2005;52(2):240–246.6
Papp K, Staab D, Harper J, et al. Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis. International Journal of Dermatology. Dec 2004;43(12):978–983.6
Park CW, Lee BH, Lee CH. Tacrolimus reduces staphylococcal colonization on the skin in Korean atopic dermatitis patients. Drugs Under Experimental & Clinical Research. 2005;31(2):77–87.2
Patel RR, Vander Straten MR, Korman NJ. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Archives of Dermatology. Sep 2003;139(9):1184–1186.6
Patel TS, Greer SC, Skinner RB, Jr. Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians. American Journal of Clinical Dermatology. 2007;8(4):189–194.6
Paul C, Cork M, Rossi AB, Papp KA, Barbier N, de Prost Y. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics. Jan 2006;117(1):e118–128.6
Reitamo S. 0.1% tacrolimus ointment is an effective treatment for adults with moderate or severe atopic dermatitis. J Eur Acad Dermatol Cenereol. 2003;17:20–31.6
Remitz A, Harper J, Rustin M, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. Acta Dermato-Venereologica. 2007;87(1):54–61.6
Ricci G, Dondi A, Patrizi A. Role of topical calcineurin inhibitors on atopic dermatitis of children. Current Medicinal Chemistry. 2007;14(14):1579–1591.6
Rikkers SM, Holland GN, Drayton GE, Michel FK, Torres MF, Takahashi S. Topical tacrolimus treatment of atopic eyelid disease. American Journal of Ophthalmology. Mar 2003;135(3):297–302.6
Rodriguez-Martin M, Saez-Rodriguez M, Carnerero-Rodriguez A, et al. Treatment of perioral dermatitis with topical pimecrolimus. Journal of the American Academy of Dermatology. Mar 2007;56(3):529–530.6
Ruiz-Maldonado R. Pimecrolimus related crusted scabies in an infant. Pediatric Dermatology. May–Jun 2006;23(3):299–300.6
Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug for the turn of the millennium? Archives of Dermatology. May 1999;135(5):574–580.6
Salavec M, Buckova H. [First experiences with 1% pimecrolimus cream therapy in prevention of atopic eczema flares in children]. Ceskoslovenska Dermatologie. 2004;79(1):3–7.1
Sand C. Topical tacrolimus ointment may induce skin tags in treated patients. Acta Dermato-Venereologica. 2003;83(4):317.6
Schiffner R, Schiffner-Rohe J, Landthaler M, Stolz W. Treatment of atopic dermatitis and impact on quality of life: a review with emphasis on topical non-corticosteroids. Pharmacoeconomics. 2003;21(3):159–179.6
Schurmeyer-Horst F, Luger TA, Bohm M. Long-term efficacy of occlusive therapy with topical pimecrolimus in severe dyshidrosiform hand and foot eczema. Dermatology. 2007;214(1):99–100.6
Segura S, Romero D, Carrera C, Iranzo P, Estrach T. Eczema herpeticum during treatment of atopic dermatitis with 1% pimecrolimus cream. Acta Dermato-Venereologica. 2005;85(6):524–525.6
Shainhouse T, Eichenfield LF. Long-term safety of tacrolimus ointment in children treated for atopic dermatitis. Expert Opinion on Drug Safety. Sep 2003;2(5):457–465.6
Simon D, Lubbe J, Wuthrich B, et al. Benefits from the use of a pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice. Analysis of a Swiss cohort. Dermatology. 2006;213(4):313–318.6
Simpson D, Noble S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs. 2005;65(6):827–858.6
Singalavanija S, Noppakun N, Limpongsanuruk W, et al. Efficacy and safety of tacrolimus ointment in pediatric Patients with moderate to severe atopic dermatitis. Journal of the Medical Association of Thailand. Nov 2006;89(11):1915–1922.6
Skaehill PA. Tacrolimus in dermatologic disorders. Annals of Pharmacotherapy. May 2001;35(5):582–588.6
Staab D, Pariser D, Gottlieb AB, et al. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label study. Pediatric Dermatology. Sep–Oct 2005;22(5):465–471.6
Tan J, Langley R. Safety and efficacy of tacrolimus ointment 0.1% (Protopic) in atopic dermatitis: a Canadian open-label multicenter study. Journal of Cutaneous Medicine & Surgery. Jul–Aug 2004;8(4):213–219.6
Thaci D, Steinmeyer K, Ebelin M-E, Scott G, Kaufmann R. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study. Dermatology. 2003;207(1):37–42.6
Thelmo MC, Lang W, Brooke E, et al. An open-label pilot study to evaluate the safety and efficacy of topically applied tacrolimus ointment for the treatment of hand and/or foot eczema. Journal of Dermatological Treatment. Sep 2003;14(3):136–140.6
Thestrup-Pedersen K. Tacrolimus treatment of atopic eczema/dermatitis syndrome. Current Opinion in Allergy & Clinical Immunology. Oct 2003;3(5):359–362.6
Virtanen HM, Reitamo S, Kari M, Kari O. Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study. Acta Ophthalmologica Scandinavica. Oct 2006;84(5):693–695.6
Weinberg JM. Formulary review of therapeutic alternatives for atopic dermatitis: focus on pimecrolimus. Journal of Managed Care Pharmacy. Jan–Feb 2005;11(1):56–64.6
Weinberg JM, Bowerman JG, Brown SM, et al. Atopic dermatitis: a new treatment paradigm using pimecrolimus. Journal of Drugs in Dermatology: JDD. Apr 2003;2(2):131–140.6
Wellington K, Jarvis B. Spotlight on topical pimecrolimus in atopic dermatitis. American Journal of Clinical Dermatology. 2002;3(6):435–438.6
Wellington K, Noble S. Pimecrolimus: a review of its use in atopic dermatitis. American Journal of Clinical Dermatology. 2004;5(6):479–495.6
Yeung CK, Ma KC, Chan HHL. Efficacy and safety of tacrolimus ointment monotherapy in chinese children with atopic dermatitis. SKINmed. Jan–Feb 2006;5(1):12–17.6

From: Appendix C, Excluded studies

Cover of Drug Class Review: Topical Calcineurin Inhibitors
Drug Class Review: Topical Calcineurin Inhibitors: Final Report [Internet].
Lee NJ, McDonagh M, Chan B, et al.
Portland (OR): Oregon Health & Science University; 2008 Oct.
Copyright © 2008, Oregon Health & Science University, Portland, Oregon.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.